<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656212</url>
  </required_header>
  <id_info>
    <org_study_id>08847002</org_study_id>
    <secondary_id>1R01AT008310-01</secondary_id>
    <nct_id>NCT02656212</nct_id>
  </id_info>
  <brief_title>Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)</brief_title>
  <acronym>Epicatechin</acronym>
  <official_title>Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>San Diego Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Veterans Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a double-blind, randomized, placebo-controlled, single dose study of (+)-&#xD;
      epicatechin with one 30mg dose/day for a total of 7 days&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a double-blinded, placebo-controlled, randomized, Phase I study that will&#xD;
      include (+)-epicatechin dosing over seven days.&#xD;
&#xD;
        -  Subjects will meet the American Diabetes Association (ADA) criteria for pre-diabetes,&#xD;
           including impaired fasting glucose (IFG) [refer to inclusion/exclusion criteria].&#xD;
&#xD;
        -  The Project includes: 7 day evaluation of a single daily dose of synthetic&#xD;
           (+)-epicatechin in pre-diabetic individuals as compared to placebo.&#xD;
&#xD;
        -  The Project has 4 outpatient clinic study visits: screening (Visit 1), randomization&#xD;
           (Visit 2), end of study drug (Visit 3), follow up end of study (Visit 4).&#xD;
&#xD;
        -  This Project has 2 telephone visits&#xD;
&#xD;
      Primary hypothesis: As these studies are designed to evaluate safety and tolerability, there&#xD;
      is no primary hypothesis to test.&#xD;
&#xD;
      Primary outcome measures. Vital signs and safety labs: BP, HR, creatinine, alkaline&#xD;
      phosphatase, and liver transaminases&#xD;
&#xD;
      These studies will provide initial data about if (+)-epicatechin can influence glycemic&#xD;
      control in individuals with prediabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in major safety endpoints: Blood Pressure (BP)</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Clinically significant differences in the major safety endpoints are defined as: BP (10 mm Hg change)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in major safety endpoints: Heart Rate (HR)</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Clinically significant differences in the major safety endpoints are defined as: HR (10 bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in major safety endpoints: Kidney Function</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Clinically significant differences in the major safety endpoints are defined as: creatinine (&gt;1.5 ULN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in major safety endpoints: Hepatic Function</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Clinically significant differences in the major safety endpoints are defined as: highly conservative changes in alkaline phosphatase and liver transaminases (&gt;1.5 ULN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline: Glucose</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Change from baseline of glucose (mg/dL) as measured from fasting labs collected at Visits 2 and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline: Insulin</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Change from baseline of insulin (uIU/ml) as measured from fasting labs collected at Visits 2 and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline: C-Peptide</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Change from baseline of C-Peptide (ng/mL) as measured from fasting labs collected at Visits 2 and 3.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>(+)-epicatechin 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects will be randomized to a 30mg dose of synthetic (+)-epicatechin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 subjects will be randomized to a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epicatechin</intervention_name>
    <description>30 mg (+)-epicatechin, taken orally, one pill/day in the morning</description>
    <arm_group_label>(+)-epicatechin 30mg</arm_group_label>
    <other_name>122158</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill, taken orally, one pill/day in the morning</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre-diabetic based on medical history and screening results&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Must be 21 to 75 years of age (inclusive)&#xD;
&#xD;
          -  Able to give informed consent to the procedures&#xD;
&#xD;
          -  If female, must be either postmenopausal or test negative for pregnancy at screening&#xD;
             and on the day of the procedure. Women on estrogen therapy will be included.&#xD;
&#xD;
          -  If female of childbearing potential, must practice and be willing to continue to&#xD;
             practice appropriate birth control during the entire duration of the study&#xD;
&#xD;
          -  Medication use stable for 4 weeks prior to screening&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 27 kg/m2&#xD;
&#xD;
          -  Definition of pre-diabetes: impaired fasting glucose (IFG, fasting glucose = 100-125&#xD;
             mg/dL) and/OR elevated HbA1c (5.7-6.4%), each in the absence of other risk factors for&#xD;
             diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Younger than 21 or older than 75 years of age&#xD;
&#xD;
          -  Clinically significant abnormalities in liver or kidney function (&gt;3x upper limit of&#xD;
             normal (ULN)), determined in the last 6 months by a certified clinical laboratory&#xD;
&#xD;
          -  Recent myocardial infarct or stroke (within 6 months of screening)&#xD;
&#xD;
          -  Blood pressure (BP) &gt;160 mmHg Systolic and &gt;100 mmHg Diastolic&#xD;
&#xD;
          -  Medications - thiazolidinediones, any steroids, anti-depressants, weight loss drugs&#xD;
&#xD;
          -  Other diseases, besides type 2 diabetes, influencing carbohydrate metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert R Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Veterans Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMR Center for Metabolic Research VASDHS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Veterans Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Robert R. Henry, MD</investigator_full_name>
    <investigator_title>Chief, Section of Diabetes, Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <keyword>epicatechin</keyword>
  <keyword>pre-diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

